Watch TherapeuticsMD Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation
TherapeuticsMD Inc (TXMD) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of TherapeuticsMD Inc stock $0.90, price $1.74, that is 48.3% below the price, quality 58 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
TI
Thin data
Nov 7, 2026
Thin data
Nov 7, 2026
TherapeuticsMD Inc
TXMD · USSolid, but very expensive
Our calculation puts a fair price 48% below what the stock costs today.
Generates free cash flow
Quality 58/100
Revenue last quarter 9% below a year ago.
Fair value $0.9000 · Strongly overvalued
Weak Growth (revenue 5y −45.8 %/yr in USD)
Loss-making · -6.6% net margin (TTM)
High debt
Trails peers (3/11)
Narrow moat 10/100
Thin data
Watch TherapeuticsMD Inc for free: we tell you when fair value or trend changes.
Watch for free
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range $0.7300 – $47.50 · fair‑value band $0.6700 – $1.14 · the $1.74 price screens above the $0.9000 fair value. As of Nov 7, 2026.
Follow TherapeuticsMD in your weekly email
Every Wednesday you see whether TherapeuticsMD is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally.
Show moreShow less
Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system.
The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors.
TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Stock analysis
TherapeuticsMD Inc (TXMD) currently trades at $1.74, while our model-based Fair Value estimate is $0.9000, 48% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.6700 (bear) to $1.14 (bull), the price of $1.74 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
TherapeuticsMD Inc reported revenue of $3.0M in FY2025 versus $2.6M in FY2021, a compound +4.1%/yr. Reported net income was −$569K in FY2025.
Key figures
Market cap $20.3M Micro · P/S ratio 6.48 · EPS (TTM) $−0.0400 · Net margin −18.8% · Return on equity −1.1% · Return on assets (EBIT) −17.8% (5-year average) · Operating margin −32.2% · Revenue (TTM) $3.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (medium confidence).
What moves the price
The share trades about 37% below its 52-week high and 37% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −48%, TXMD screens richer than that median.
Fair Value models
Bear $0.6700
Fair Value $0.9000
Bull $1.14
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/Revenue
$0.6700
$0.9000
$1.14
54
NCAV (Graham)
$0.2100
$0.3200
$0.4000
54
All 2 models by family
Multiples
EV/Revenue
$0.6700
$0.9000
$1.14
54
Asset-Based
NCAV (Graham)
$0.2100
$0.3200
$0.4000
54
Quality Score breakdown
Overall quality
58/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability
6
How much profit the company makes from its sales and capital
Quality Growth
72
Are margins and returns getting better?
Cashflow
100
Do the profits arrive as real cash?
Financial strength
42
Debt, balance sheet and risk of trouble
Investment
100
Does it invest with discipline instead of growing at any price?
Low Volatility
44
How calm the share price moves, does not count
Price momentum
51
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high
58
Distance to the 52-week high, does not count
New shares
60
Buys back shares or issues new ones?
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
- BuyTommy G ThompsonDirector8,400 shares at $1.67$14,028Dec 23, 2025
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
21/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+71.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−64.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−45.8%
Start year 2020 (pandemic). Over 10 years: −17.3% a year
Revenue growth 32 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
’13
’14
’15
’16
’17
’18
’19
’20
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−239.8% (2020) → −139.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+38.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +35.5% a year for the price.
TXMD screens overvalued: fair value 48% below the price. Compare with Merck KGaA →
Compare TherapeuticsMD Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Revenue growth by industry
- PEG ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $79.40 | $113.53 | +43% | vs TXMD |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.23 | ¥55.21 | +12% | vs TXMD |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,905 | ₹1,947 | +2% | vs TXMD |
| Haleon plc HLN | $9.14 | $8.61 | −6% | vs TXMD |
| Merck KGaA MRK | €149.20 | €109.18 | −27% | vs TXMD |
| Galderma Group GALD | CHF 190.65 | CHF 109.86 | −42% | vs TXMD |
| Takeda Pharmaceutical Company TAK | $21.02 | $11.31 | −46% | vs TXMD |
| Teva Pharmaceutical Industries Limited TEVA | $42.61 | $20.74 | −51% | vs TXMD |
| Sandoz Group SDZ | CHF 84.46 | CHF 39.70 | −53% | vs TXMD |
| Divi's Laboratories Limited DIVISLAB | ₹11,566 | ₹1,567 | −86% | vs TXMD |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Free calculator
Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
For bloggers & editors: embed code + live data
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "TherapeuticsMD Inc Fair Value". https://www.fairvalue-calculator.com/stock/TXMD
Frequently asked questions
Is TherapeuticsMD Inc (TXMD) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $0.9000 versus a price of $1.74, about 48% lower (overvalued).
What is the fair value of TXMD?
Our model-based fair value for TherapeuticsMD Inc is $0.9000 (as of Nov 7, 2026), built from audited fundamentals. The current price: $1.74.
What is the quality score of TXMD?
TherapeuticsMD Inc has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TherapeuticsMD Inc (TXMD)?
Our model-based price target is the fair value of $0.9000 (as of Nov 7, 2026) from 2 valuation models. Cautious scenario $0.6700, optimistic scenario $1.14. It is a calculation from audited fundamentals, not an analyst target.
What is the TherapeuticsMD Inc stock forecast for 2026?
Our models put fair value at $0.9000, about 48% lower versus a price of $1.74 (overvalued). Cautious scenario $0.6700, optimistic scenario $1.14. The calculation is refreshed regularly with new filings.
What is the revenue of TherapeuticsMD Inc (TXMD)?
TherapeuticsMD Inc reported trailing-twelve-month revenue of about $3.3M (latest available figure, as of Nov 7, 2026).
What growth is priced into TherapeuticsMD Inc (TXMD)?
For today's price to be fair in a discounted-cash-flow model, TherapeuticsMD Inc would have to grow free cash flow by +38.7 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -45.8 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of TXMD use?
Our models discount TherapeuticsMD Inc at 8.9 %: a base by market capitalisation (nano), damped by beta 0.65, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For TherapeuticsMD Inc that is +38.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has TherapeuticsMD Inc (TXMD) delivered so far?
Over the past 5 years revenue at TherapeuticsMD Inc grew -45.8 % a year. The price currently implies free-cash-flow growth of +38.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of TherapeuticsMD Inc (TXMD) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into TherapeuticsMD Inc (+38.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of TherapeuticsMD Inc (TXMD)?
The free-cash-flow yield on the price is 11.97 %: that much free cash flow TherapeuticsMD Inc produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of TherapeuticsMD Inc (TXMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TherapeuticsMD Inc it is $0.9000 per share (as of Nov 7, 2026), against a price of $1.74. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is TherapeuticsMD Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, TXMD trades above its calculated fair value: price $1.74, fair value $0.9000, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TXMD?
No. The price is what the market pays today ($1.74); the fair value is what the company's own numbers justify ($0.9000). For TherapeuticsMD Inc the two are $0.8400 per share apart. That gap is exactly why we show both numbers side by side.
How much is TherapeuticsMD Inc worth?
The market values TherapeuticsMD Inc at about $20.3M (market capitalisation, as of Nov 7, 2026). Per share that is $1.74; our models calculate a fair value of $0.9000 per share.
What do the bullish and bearish scenarios say about TXMD?
Our models span a range for TherapeuticsMD Inc: cautious scenario $0.6700, base $0.9000, optimistic $1.14 per share (as of Nov 7, 2026, price $1.74). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of TherapeuticsMD Inc (TXMD)?
Balance-sheet figures for TherapeuticsMD Inc (as of Nov 7, 2026): return on equity −1.1%, debt of 8.84 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is TXMD from its 52-week high?
TherapeuticsMD Inc trades at $1.74, about 37% below its 52-week high of $2.77 and 37% above the low of $1.27 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.9000 is for.
Which stocks are comparable to TherapeuticsMD Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TherapeuticsMD Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $1.74, calculated fair value $0.9000 (−48%), Quality Score 58/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TXMD calculated?
We run TherapeuticsMD Inc through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.9000 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. TherapeuticsMD Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TherapeuticsMD Inc (TXMD)?
The closing price on Nov 6, 2026 was $1.74. Our model-based fair value is $0.9000, about 48% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TherapeuticsMD Inc right now?
The price sits above even our optimistic bull case ($1.14). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of TherapeuticsMD Inc
How large is the market capitalisation of TherapeuticsMD Inc (TXMD)?
The market capitalisation of TherapeuticsMD Inc is $20.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TherapeuticsMD Inc (TXMD)?
The price-to-sales ratio of TherapeuticsMD Inc is 6.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of TherapeuticsMD Inc (TXMD)?
Earnings per share at TherapeuticsMD Inc are $−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of TherapeuticsMD Inc (TXMD)?
The net margin of TherapeuticsMD Inc is −18.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TherapeuticsMD Inc (TXMD)?
The return on equity (ROE) of TherapeuticsMD Inc is −1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TherapeuticsMD Inc (TXMD)?
On an EBIT basis the return on assets of TherapeuticsMD Inc is −17.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TherapeuticsMD Inc (TXMD)?
The operating margin of TherapeuticsMD Inc is −32.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TherapeuticsMD Inc (TXMD)?
Revenue at TherapeuticsMD Inc is growing −8.7% versus a year earlier (3y avg −64.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TherapeuticsMD Inc (TXMD)?
Earnings per share at TherapeuticsMD Inc are growing −80.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does TherapeuticsMD Inc (TXMD) hold?
TherapeuticsMD Inc holds more cash than debt, $1.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch TherapeuticsMD Inc in the live analysis
One click puts TherapeuticsMD Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.